148 related articles for article (PubMed ID: 37543865)
1. Fenfluramine in the treatment of Dravet syndrome: Results of a third randomized, placebo-controlled clinical trial.
Sullivan J; Lagae L; Cross JH; Devinsky O; Guerrini R; Knupp KG; Laux L; Nikanorova M; Polster T; Talwar D; Ceulemans B; Nabbout R; Farfel GM; Galer BS; Gammaitoni AR; Lock M; Agarwal A; Scheffer IE;
Epilepsia; 2023 Oct; 64(10):2653-2666. PubMed ID: 37543865
[TBL] [Abstract][Full Text] [Related]
2. Fenfluramine for Treatment-Resistant Seizures in Patients With Dravet Syndrome Receiving Stiripentol-Inclusive Regimens: A Randomized Clinical Trial.
Nabbout R; Mistry A; Zuberi S; Villeneuve N; Gil-Nagel A; Sanchez-Carpintero R; Stephani U; Laux L; Wirrell E; Knupp K; Chiron C; Farfel G; Galer BS; Morrison G; Lock M; Agarwal A; Auvin S;
JAMA Neurol; 2020 Mar; 77(3):300-308. PubMed ID: 31790543
[TBL] [Abstract][Full Text] [Related]
3. Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial.
Lagae L; Sullivan J; Knupp K; Laux L; Polster T; Nikanorova M; Devinsky O; Cross JH; Guerrini R; Talwar D; Miller I; Farfel G; Galer BS; Gammaitoni A; Mistry A; Morrison G; Lock M; Agarwal A; Lai WW; Ceulemans B;
Lancet; 2019 Dec; 394(10216):2243-2254. PubMed ID: 31862249
[TBL] [Abstract][Full Text] [Related]
4. Don't Fear the Reefer-Evidence Mounts for Plant-Based Cannabidiol as Treatment for Epilepsy.
Perry MS
Epilepsy Curr; 2019; 19(2):93-95. PubMed ID: 30955420
[TBL] [Abstract][Full Text] [Related]
5. Improved everyday executive functioning following profound reduction in seizure frequency with fenfluramine: Analysis from a phase 3 long-term extension study in children/young adults with Dravet syndrome.
Bishop KI; Isquith PK; Gioia GA; Gammaitoni AR; Farfel G; Galer BS; Nabbout R; Wirrell EC; Polster T; Sullivan J
Epilepsy Behav; 2021 Aug; 121(Pt A):108024. PubMed ID: 34023810
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of fenfluramine in patients with Dravet syndrome: A meta-analysis.
Zhang L; Li W; Wang C
Acta Neurol Scand; 2021 Apr; 143(4):339-348. PubMed ID: 33336426
[TBL] [Abstract][Full Text] [Related]
7. Fenfluramine significantly reduces day-to-day seizure burden by increasing number of seizure-free days and time between seizures in patients with Dravet syndrome: A time-to-event analysis.
Sullivan J; Specchio N; Devinsky O; Auvin S; Perry MS; Strzelczyk A; Gil-Nagel A; Dai D; Galer BS; Gammaitoni AR
Epilepsia; 2022 Jan; 63(1):130-138. PubMed ID: 34676542
[TBL] [Abstract][Full Text] [Related]
8. Fenfluramine HCl (Fintepla
Sullivan J; Scheffer IE; Lagae L; Nabbout R; Pringsheim M; Talwar D; Polster T; Galer B; Lock M; Agarwal A; Gammaitoni A; Morrison G; Farfel G
Epilepsia; 2020 Nov; 61(11):2396-2404. PubMed ID: 33078386
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Fenfluramine for the Treatment of Seizures Associated With Lennox-Gastaut Syndrome: A Randomized Clinical Trial.
Knupp KG; Scheffer IE; Ceulemans B; Sullivan JE; Nickels KC; Lagae L; Guerrini R; Zuberi SM; Nabbout R; Riney K; Shore S; Agarwal A; Lock M; Farfel GM; Galer BS; Gammaitoni AR; Davis R; Gil-Nagel A
JAMA Neurol; 2022 Jun; 79(6):554-564. PubMed ID: 35499850
[TBL] [Abstract][Full Text] [Related]
10. Dose-Ranging Effect of Adjunctive Oral Cannabidiol vs Placebo on Convulsive Seizure Frequency in Dravet Syndrome: A Randomized Clinical Trial.
Miller I; Scheffer IE; Gunning B; Sanchez-Carpintero R; Gil-Nagel A; Perry MS; Saneto RP; Checketts D; Dunayevich E; Knappertz V;
JAMA Neurol; 2020 May; 77(5):613-621. PubMed ID: 32119035
[TBL] [Abstract][Full Text] [Related]
11. An examination of the efficacy and safety of fenfluramine in adults, children, and adolescents with Dravet syndrome in a real-world practice setting: A report from the Fenfluramine European Early Access Program.
Guerrini R; Specchio N; Aledo-Serrano Á; Pringsheim M; Darra F; Mayer T; Gil-Nagel A; Polster T; Zuberi SM; Lothe A; Gammaitoni A; Strzelczyk A
Epilepsia Open; 2022 Dec; 7(4):578-587. PubMed ID: 35801621
[TBL] [Abstract][Full Text] [Related]
12. Fenfluramine for treatment-resistant epilepsy in Dravet syndrome and other genetically mediated epilepsies.
Sullivan J; Simmons R
Drugs Today (Barc); 2021 Jul; 57(7):449-454. PubMed ID: 34268532
[TBL] [Abstract][Full Text] [Related]
13. Comparative short-term efficacy and safety of add-on anti-seizure medications in Dravet syndrome: An indirect treatment comparison.
Devi N; Madaan P; Asrar MM; Sahu JK; Bansal D
Seizure; 2021 Oct; 91():316-324. PubMed ID: 34274891
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular safety of fenfluramine in the treatment of Dravet syndrome: Analysis of an ongoing long-term open-label safety extension study.
Lai WW; Galer BS; Wong PC; Farfel G; Pringsheim M; Keane MG; Agarwal A
Epilepsia; 2020 Nov; 61(11):2386-2395. PubMed ID: 32809271
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and tolerability of fenfluramine in patients with Dravet syndrome: A systematic review and meta-analysis.
Sharawat IK; Panda PK; Kasinathan A; Panda P; Dawman L; Joshi K
Seizure; 2021 Feb; 85():119-126. PubMed ID: 33461030
[TBL] [Abstract][Full Text] [Related]
16. Lamotrigine adjunctive therapy among children and adolescents with primary generalized tonic-clonic seizures.
Trevathan E; Kerls SP; Hammer AE; Vuong A; Messenheimer JA
Pediatrics; 2006 Aug; 118(2):e371-8. PubMed ID: 16847080
[TBL] [Abstract][Full Text] [Related]
17. Fenfluramine treatment is associated with improvement in everyday executive function in preschool-aged children (<5 years) with Dravet syndrome: A critical period for early neurodevelopment.
Bishop KI; Isquith PK; Gioia GA; Knupp KG; Scheffer IE; Nabbout R; Specchio N; Sullivan J; Auvin S; Helen Cross J; Guerrini R; Farfel G; Galer BS; Gammaitoni AR
Epilepsy Behav; 2023 Jan; 138():108994. PubMed ID: 36463826
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of adjunctive antiseizure medications for dravet syndrome: A systematic review and network meta-analysis.
Wu J; Zhang L; Zhou X; Wang J; Zheng X; Hu H; Wu D
Front Pharmacol; 2022; 13():980937. PubMed ID: 36120377
[No Abstract] [Full Text] [Related]
19. Fenfluramine repurposing from weight loss to epilepsy: What we do and do not know.
Odi R; Invernizzi RW; Gallily T; Bialer M; Perucca E
Pharmacol Ther; 2021 Oct; 226():107866. PubMed ID: 33895186
[TBL] [Abstract][Full Text] [Related]
20. Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome.
Devinsky O; Cross JH; Laux L; Marsh E; Miller I; Nabbout R; Scheffer IE; Thiele EA; Wright S;
N Engl J Med; 2017 May; 376(21):2011-2020. PubMed ID: 28538134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
